1276.HK
600276.SHG

Pharmaceutical company Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) said on Sunday that executive director and senior vice president Sun Jieping will sell up to 476,700 of his A-shares in the company for personal reasons. Hengrui said Sun, who is the company’s deputy general manager, will sell the stock via centralized bidding during the three months starting 15 trading days after the disclosure.

Sun holds about 1.9 million Hengrui shares, accounting for roughly 0.029% of its total share capital, predominantly acquired through equity incentive plans. His planned sale represents about 0.007% of the company’s total share capital.

Hengrui is listed in Shanghai and made a second listing in Hong Kong at the end of last month. The offering was oversubscribed by about 454 times, with the international portion oversubscribed by 16 times. It priced its Hong Kong shares at HK$44.05 each, raising nearly HK$10 billion ($1.27 billion).

Shares of Hengrui opened down 0.5% at HK$57.50 on Monday. The stock is up around 30% from its Hong Kong listing price.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

WeRide is enjoying a payoff from expanding its global taxi flee

Robotaxi rollout drives faster earnings pace at WeRide

The driverless technology company is enjoying a payoff from expanding its global taxi fleet, with quarterly revenues surging and losses continuing to shrink Key Takeaways: Third-quarter revenue more than doubled,…
Illustration of Luckin and Costa coffee being tasted

Luckin Coffee eyes global leap as China’s Double 11 loses its luster

Luckin could be preparing a bid for Costa Coffee. What's driving this potential deal, and what are its chances for success? And this year's Double 11 festival looks like a dud, with most big e-commerce companies failing to publish any big numbers. What does the future hold for this fast-fading shopping fest?